Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
about
Progress and prospects of long noncoding RNAs in lipid homeostasisUndernutrition during suckling in rats elevates plasma adiponectin and its receptor in skeletal muscle regardless of diet composition: a protective effect?Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in miceRole of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver diseasePeroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effectEffects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOWProtection of neurons and microglia against ethanol in a mouse model of fetal alcohol spectrum disorders by peroxisome proliferator-activated receptor-γ agonists.Effects of PPARα/PGC-1α on the energy metabolism remodeling and apoptosis in the doxorubicin induced mice cardiomyocytes in vitro.Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventionsInsulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instabilityPioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trialBanting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusRole of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignanciesCurrent role of fenofibrate in the prevention and management of non-alcoholic fatty liver diseaseNew diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study.Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus.Cardiometabolic impact of non-statin lipid lowering therapies.Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.Retinoic acid receptor β2 agonists restore glycaemic control in diabetes and reduce steatosis.Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.Identification of Eupatilin from Artemisia argyi as a Selective PPARα Agonist Using Affinity Selection Ultrafiltration LC-MS.Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines.Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease.Identification of a proliferator-activated receptor-γ antagonist for the treatment of type 2 diabetes mellitus.Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.Metabolic adaptation to intermittent fasting is independent of peroxisome proliferator-activated receptor alpha.Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes.Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.Arctigenin Inhibits Liver Cancer Tumorigenesis by Inhibiting Gankyrin Expression via C/EBPα and PPARα.
P2860
Q26765495-F4CC532F-BDC8-44F0-A942-57FE607FD75EQ28566924-0D1DBA4D-6A9A-4DF6-BE33-9B74DE5EA978Q30513404-BC8FF3F7-4F92-4827-8D0B-0C481FA7527DQ33607697-B2217B66-2409-4042-A1F7-B805890A7961Q33753420-AA398B7B-AA4F-45E2-992A-AA648AD3880AQ33786881-9D56BA58-7AB6-49E3-A520-8ABEE41243EEQ34036950-38431CA8-401D-4AD5-BCB5-73DEB868D06DQ34041838-39A5800B-DA06-48F0-BB3C-CB14CD302544Q34264630-7885B465-086E-4F8D-9F78-A347C70B7BADQ35015002-8A3C2AB6-3271-437F-B806-8E9EF835438CQ36375069-9CF81493-EEF0-4CE6-9E29-A62E1A85A4C3Q36740436-1A5B96CB-2997-4973-A0EF-C9103BA8F4B4Q36741853-C8CE8448-74E5-4815-8D9B-8395CB152173Q36972810-E47A9D5C-A21C-4B25-A9D1-8C2929C3BBB7Q37141727-266417DA-2B20-4E3D-BE73-5B18BFC3C7EBQ37182794-230F4979-AB83-4677-AE04-C94756E74B16Q37196514-CEA5A531-1DCC-4D55-871A-5F09B4105E08Q37437435-CAF79B03-FF8F-4438-BD02-FCBA5BA74545Q37577126-5A38471F-F8EB-4ABF-9336-3AC630DCED82Q37577162-A747AC3D-2613-4D25-B47A-2467A36291F0Q37640263-9994B29F-7348-43CC-9BA7-5BD835159321Q37737476-F0510D6B-2D34-438B-B217-6F126C856EFBQ37831911-C10A2D6C-A1A5-436A-85BF-A0573763684CQ38176275-628B27A3-A63F-412A-B293-98E0D5A62B39Q38222135-060BB032-80C9-41C2-846C-1DDCC45D3093Q38296029-909B4FB5-2934-40B9-8FBE-1E13890CC463Q38325814-A5410A56-8749-4B77-915F-A2A8F7C4BFC4Q38752520-8428B619-983D-43FC-BFB8-FC51BA93FB71Q38847849-249CEC9C-7058-46AC-AC36-2B917FDA4C76Q39332865-EAB6C79C-9857-44C2-9C33-8CB43C27FB4CQ40958800-959798E5-BEEA-4CCF-85E2-2C5331FD22C1Q42036117-503636E7-B5D4-4537-9C66-0A438CECFECAQ44695536-002AFBFF-6DFC-4A79-85C0-8552661D4495Q45403785-AF0EBE1A-A7DE-4047-80DE-DA2F8DF75D6AQ47394446-E352A9B3-768F-4D2F-A29F-D806E15DD5D1Q47785505-41D87407-D527-47DF-A5D9-C034E13D5657Q50976554-0592CF2C-11FC-4E99-8088-C7ED0281206CQ50988205-F72C1894-9848-4227-BE93-2593F7F4C9D7Q51311315-C32C0AFE-FE65-4B20-9A51-BBDBB2E9AE2DQ52595227-A1B32571-A629-4670-A2E5-89B7D791B8F5
P2860
Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Effects of peroxisome prolifer ...... with type 2 diabetes mellitus.
@en
Effects of peroxisome proliferator-activated receptor
@nl
type
label
Effects of peroxisome prolifer ...... with type 2 diabetes mellitus.
@en
Effects of peroxisome proliferator-activated receptor
@nl
prefLabel
Effects of peroxisome prolifer ...... with type 2 diabetes mellitus.
@en
Effects of peroxisome proliferator-activated receptor
@nl
P2093
P2860
P1433
P1476
Effects of peroxisome prolifer ...... with type 2 diabetes mellitus.
@en
P2093
P2860
P2888
P304
P356
10.1007/S00125-007-0698-9
P577
2007-05-23T00:00:00Z